

Tremfya® (guselkumab)
Effective 03/01/2023

Plan	<input type="checkbox"/> MassHealth <input checked="" type="checkbox"/> MassHealth (PUF) <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Tremfya (guselkumab) is an interleukin-23 blocker (IL-23) indicated for:

- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members new to the plan who are currently receiving treatment with Tremfya excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

Psoriatic Arthritis (PsA)

Prescriber provides documentation of ALL of the following:

1. Diagnosis of psoriatic arthritis
2. **BOTH** of the following:
 - a. Paid claims or physician documented inadequate response, adverse reaction, or contraindication to Stelara
 - b. Paid claims or physician documented inadequate response or adverse reaction to **ONE** or contraindication to **ALL** anti-TNF agent that is FDA-approved for the requested indication
3. Appropriate dosing †



Plaque Psoriasis

Prescriber provides documentation of **ALL** of the following:

1. Diagnosis of moderate to severe plaque psoriasis
2. **ONE** of the following:
 - a. Paid claims or physician documented inadequate response or adverse reaction to **ONE** conventional therapy or contraindication to **ALL** conventional therapies (see appendix B)
 - i. topical agent
 - ii. phototherapy
 - iii. systemic agent
 - b. Paid claims or physician documented inadequate response or adverse reaction to **ONE** biologic DMARD that is FDA-approved for plaque psoriasis
3. Appropriate dosing †
4. Prescriber provides clinical rationale for use of Tremfya® instead of Stelara®

† Requests for more frequent or higher doses – see Appendix

Off-Label Indications

Pityriasis rubra pilaris (PRP)

Prescriber provides documentation of **ALL** of the following:

1. Diagnosis of pityriasis rubra pilaris (PRP)
2. Paid claims or physician documented inadequate response or adverse reaction to **ONE** topical corticosteroid or contraindication to **ALL** topical corticosteroids
3. Clinical rationale for use of the requested agent instead of Stelara® and Taltz®

New members currently stable on Tremfya® can be approved without documentation of failed trials with the conventional therapies.

Continuation of Therapy

Reauthorization requires physician documentation of a positive response to therapy.

Limitations

1. Initial approvals will be granted for:
 - a. Plaque Psoriasis and Off-label indications: 3 months.
 - b. All other diagnosis: 6 months.
2. Reauthorizations will be granted for 12 months
3. The following quantity limits apply:

Tremfya Inj 100mg/mL	100mg per 8 weeks
Tremfya Pen Inj 100mg/mL	

Appendix A: Dosing

Tremfya® (guselkumab)	Plaque Psoriasis: <u>SQ</u> : 100 mg initially at week 0 and 4; followed by 100 mg every eight weeks
--------------------------	--

Appendix B. Conventional Therapies for Plaque Psoriasis

Conventional Treatment Lines	Agents Used
------------------------------	-------------



Topical Agents	emollients, keratolytics, corticosteroids, coal tar, anthralin, calcipotriene, tazarotene, calcitriol, calcineurin inhibitors
Systemic Agents	Traditional DMARDs: methotrexate, apremilast, acitretin,
Phototherapy	ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA), narrow band UV-B (NUVB)

Appendix C: More Frequent/High Doses

Requests for more frequent or higher doses of injectable biologics may be approved if **ALL** of the following is provided:

1. Documentation of severe disease
2. **ONE** of the following:
 - a. Paid claims or physician documented inadequate response or adverse reaction to **ONE** other injectable biologic which is FDA-approved for the requested indication
 - b. Contraindication to **ALL** other injectable biologics which are FDA-approved for the requested indication
3. Documented partial response to FDA-approved dosing of current biologic therapy
4. Documentation of specialist consult for the requested indication

References

1. Tremfya [package insert]. Horsham, PA: Janssen Biotech, Inc.; October 2017.
2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol.* 2009; 61:451-485.
3. Reich K, Armstrong, AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. *Am J Clin Dermatol.* 2017;76(3):418-431.
4. Blauvelt A, Papp KA, Griffiths, CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. *Am J Clin Dermatol.* 2017;76(3):405-417.
5. Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. *Br J Dermatol* 2018; 178:114.

Review History

03/01/2018: Implemented

02/20/2019: Reviewed P&T Mtg

10/21/2020 – Reviewed and Updated; separated out Comm/Exch vs. MassHealth. Matched MassHealth Preferred Unified Formulary for implementation 1/1/2021

11/17/2021 – Reviewed and Updated for Nov P&T; matched MH UPPL; updated to reflect criteria changes based on literature; added appendix for higher dose/more frequent dosing

11/17/2021 – Updated per MH UPPL: criteria for Taltz revised for psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis based on contract. Additionally, recertification criteria regarding Cosentyx requests approved for ankylosing spondylitis or non-radiographic axial spondyloarthritis prior to Taltz require was removed as this is no longer a requirement in the criteria.



Effective 01/01/2022.

01/11/2023 – Reviewed and updated for Jan P&T. Appropriate diagnosis was replaced with a specific indication throughout. Off-label indications added for: PRP. Added language regarding stability of requested medication for new members. Effective 3/1/23.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.